Sign In
Buy ARMP
$7.01
+0.140 (+2.04%)
At Close: Jun 23, 2026
Armata data support advancing AP-SA02 to Phase 3, says H.C. Wainwright
11:37am, Wednesday, 22'nd Oct 2025
H.C. Wainwright reiterates a Buy rating and $9 price target on Armata Pharmaceuticals after the company shared new data from the recently completed Phase 2a diSArm study in a late-breaking oral presen
LOS ANGELES , Oct. 22, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu
LOS ANGELES , Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?
10:40am, Monday, 06'th Oct 2025
Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
10:42am, Thursday, 18'th Sep 2025
Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
07:00am, Monday, 08'th Sep 2025
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES , Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Thursday, 04'th Sep 2025
LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu
All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy
01:01pm, Friday, 15'th Aug 2025
Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?
10:41am, Friday, 15'th Aug 2025
Here is how Armata Pharmaceuticals, Inc. (ARMP) and Avadel (AVDL) have performed compared to their sector so far this year.
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates
06:40pm, Tuesday, 12'th Aug 2025
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
04:05pm, Tuesday, 12'th Aug 2025
Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES , Aug. 12, 2025 /PRNew
ARMP Soars 72% in a Month Following Infectious Disease Study Success
10:51am, Wednesday, 21'st May 2025
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
06:45pm, Wednesday, 14'th May 2025
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.69 per share a year ago.
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
04:05pm, Wednesday, 14'th May 2025
LOS ANGELES , May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pur
